ArticleJournal of diabetes science and technology2017
Regulation Catches Up to Reality.
Article in Journal of diabetes science and technology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Methods for Insulin Bolus Adjustment Based on the Continuous Glucose Monitoring Trend Arrows in Type 1 Diabetes: Performance and Safety Assessment in an In Silico Clinical Trial.Journal of diabetes science and technology · 2023Trial
- Federated multimodal AI for precision-equitable diabetes care.Frontiers in digital health · 2025Review
- Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control.Diabetes & metabolism journal · 2023Review
- Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials.Journal of diabetes science and technology · 2022Article
- Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach.Metabolites · 2021Article
- Glycemic variability of acute stroke patients and clinical outcomes: a continuous glucose monitoring study.Therapeutic advances in neurological disorders · 2021Article
- Article
- Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors.Sensors (Basel, Switzerland) · 2020Review
- Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review.Biomedical engineering online · 2019Review
- In Silico Assessment of Literature Insulin Bolus Calculation Methods Accounting for Glucose Rate of Change.Journal of diabetes science and technology · 2019Article
- Understanding of type 1 diabetes mellitus: what we know and where we go.Korean journal of pediatrics · 2018Article
- Modeling of Diabetes and Its Clinical Impact.Journal of diabetes science and technology · 2018Review
- Continuous Glucose Monitoring: Current Use in Diabetes Management and Possible Future Applications.Journal of diabetes science and technology · 2018Article
- Technology in the management of type 1 diabetes mellitus - current status and future prospects.Nature reviews. Endocrinology · 2018Review
- Calibration of Minimally Invasive Continuous Glucose Monitoring Sensors: State-of-The-Art and Current Perspectives.Biosensors · 2018Review
- A Neural-Network-Based Approach to Personalize Insulin Bolus Calculation Using Continuous Glucose Monitoring.Journal of diabetes science and technology · 2018Article
- Effect of BGM Accuracy on the Clinical Performance of CGM: An In-Silico Study.Journal of diabetes science and technology · 2017Article
- Retrospective Analysis of Continuous Glucose Monitoring Data With the Surveillance Error Grid Supports Nonadjunctive Dosing Decisions.Journal of diabetes science and technology · 2017Article
- Commentary Regarding Shapiro, "Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe?"Journal of diabetes science and technology · 2017Article
- A Model of Self-Monitoring Blood Glucose Measurement Error.Journal of diabetes science and technology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The FDA recently conducted an Advisory Panel meeting to evaluate the safety, efficacy, and benefits of granting a nonadjunctive label claim for the DEXCOM G5 Mobile continuous glucose monitoring (CGM) system. If approved, this claim will allow users to make day-to-day treatment decisions, including insulin dosing directly from the glucose values and rate of changes arrows generated by the CGM device, without the requirement of a confirmatory measurement with a self-monitoring blood glucose (SMBG) meter. Sporadic SMBG testing gives limited data, while CGM gives a value every 5 minutes and has alerts, alarms, trending information and allows caregivers to follow the user in real time 24/7. This indication will lead to more wide spread use of CGM and improve overall care with protection of hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.